Mutagenicity evaluation of HC Blue No. 1 and HC Blue No. 2, I. Effect on the induction of micronuclei in mouse bone marrow cells.

Mutat Res

Toxicology Division, Lilly Research Laboratories, A Division of Eli Lilly and Company, Greenfield, IN 46140.

Published: June 1990

Two hair-dye chemicals, HC Blue No. 1 and HC Blue No. 2, were assessed for the ability to produce chromosome breakage and/or spindle malformation in vivo by evaluating the capacity of these compounds to induce micronuclei in polychromatic erythrocytes of mouse bone marrow. Initial studies were conducted in ICR male and female mice given a single intraperitoneal dose of 1000, 500 or 250 mg/kg body weight and examined for micronucleus induction 24 or 48 h later. Activity was observed in female mice given 1000 mg/kg of HC Blue No. 1 at the 24-h harvest time. A questionable response was noted with HC Blue No. 2 in males at the 1000 mg/kg, 24-h time point. No activity was observed in either sex at the 48-h harvest time. In a second set of studies, mice from two strains, ICR and CD-1, were administered a single intraperitoneal dose of 1000 mg/kg of each chemical and the bone marrow was extracted 24 h later. In these experiments, HC Blue No. 1 again produced a statistically significant elevation of micronuclei in female ICR mice. No significant effect was observed in CD-1 mice of either sex. HC Blue No. 2 did not produce any significant elevation of micronuclei in either sex of ICR or CD-1 mice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0165-1218(90)90117-kDOI Listing

Publication Analysis

Top Keywords

bone marrow
12
1000 mg/kg
12
blue
8
blue blue
8
mouse bone
8
female mice
8
single intraperitoneal
8
intraperitoneal dose
8
dose 1000
8
activity observed
8

Similar Publications

Background/objectives: Understanding the dynamic changes in nutritional status of patients with non-Hodgkin's lymphoma (NHL) during chemotherapy is crucial, as it significantly impacts chemotherapy-related toxicity and survival outcomes.

Subjects/methods: This multi-center study included newly diagnosed NHL patients. Nutritional status and chemotherapy-related toxic effects were assessed over the first five chemotherapy sessions, with follow-ups conducted every 3 months.

View Article and Find Full Text PDF

Decreased STING predicts adverse efficacy in bortezomib regimens and poor survival in multiple myeloma.

Clin Exp Med

January 2025

Stem Cell Immunity and Regeneration Key Laboratory of Luzhou, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.

Purpose: STING (stimulator of interferon genes) is involved in viral and bacterial defense through interferon pathway and innate immunity. Increased susceptibility to infection is a common manifestation of multiple myeloma (MM). Thus, we aimed to explore the clinical significance and possible mechanism of STING in MM.

View Article and Find Full Text PDF

Macrophages play important roles in maintaining intestinal homeostasis and in the pathogenesis of inflammatory bowel diseases (IBDs). However, the underlying mechanisms that govern macrophage-mediated inflammation are still largely unknown. In this study, we report that RNF128 is downregulated in proinflammatory macrophages.

View Article and Find Full Text PDF

Anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma (ALCL) typically affects young individuals and, despite high responsiveness to cytotoxic drugs, relapses occur in over 50% of patients. Crizotinib has improved outcomes, but its management in patients desiring parenthood remains an issue. This study presents the first description of four successful pregnancies during crizotinib treatment for ALK+ALCL: a female patient achieving two pregnancies through assisted reproductive technologies (ART), temporarily discontinuing crizotinib and maintaining a complete remission (CR), and a male patient conceiving naturally while on continuous therapy.

View Article and Find Full Text PDF

Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis.

Thromb Haemost

January 2025

Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

Background:  V617F-mutated myeloproliferative neoplasms (MPN) exhibit abnormal proliferation of bone marrow progenitors and increased risk of thrombosis, specifically in splanchnic veins (SVT). The contribution of the endothelium to the development of the prothrombotic phenotype was explored.

Material And Methods:  Plasma and serum samples from V617F MPN patients with (n=26) or without (n=7) thrombotic debut and different treatments, were obtained (n=33).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!